DoD Increases Development Contract With Cleveland BioLabs. Print E-mail
By Staff and Wire Reports   
Friday, 01 July 2011 19:25
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 1, 2011.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced that it received a $1,531,034 increase (including option) in the development portion of the Company's existing contract, awarded on September 16, 2010, from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) Medical Identification and Treatment Systems (MITS) to fund additional development activities for CBLB502, a medical radiation countermeasure.


Also Friday:


Alere Inc. (NYSE:ALR) ("Alere") announced today that it has closed senior secured credit facilities totaling $2.1 billion.

Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against each of Amneal Pharmaceuticals, LLC ("Amneal") and Sandoz, Inc. ("Sandoz") for infringement of certain of Shire's VYVANSE patents.

Sorrento Therapeutics, Inc. (OTC Bulletin Board:SRNE)
today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases.

Urigen Pharmaceuticals, Inc. (PINKSHEETS: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced a development update and management changes.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter